Dr. Mark Gormley Quoted in the Pharmacy Times on the FDA's Approval for Botox for Pediatric Patients
The FDA officials have approved onabotulinumtoxinA (Botox) for the treatment for upper limb spasticity in children. The FDA is still reviewing the use of onabotulinumtoxinA (Botox) to treat lower limb spasticity in children, with a decision expected later this year.
Dr. Mark Gormley, Jr., Affiliate Assistant Professor in the Department of Rehabilitation Medicine and Pediatric Physiatrist at Gillette Children's Specialty Healthcare, was quoted in Pharmacy Times on the FDA's approval of Botox for the treatment of children, ages 2 to 17 years, with upper limb spasticity. He treats children with upper limb spasticity and witnesses how it can "negatively impact a child's development and quality of life". Read more about the FDA's approval of onabotulinumtoxinA (Botox) below and the impact of this decision.
